Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update
TJ Smith, K Bohlke, GH Lyman, KR Carson… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …
Colony-stimulating factors for febrile neutropenia during cancer therapy
CL Bennett, B Djulbegovic, LAB Norris… - New England Journal …, 2013 - Mass Medical Soc
A woman receives a diagnosis of diffuse large B-cell lymphoma; a standard chemotherapy
regimen is recommended. Use of prophylactic granulocyte CSF is considered. G-CSF …
regimen is recommended. Use of prophylactic granulocyte CSF is considered. G-CSF …
[HTML][HTML] Management of febrile neutropaenia: ESMO clinical practice guidelines
J Klastersky, J De Naurois, K Rolston… - Annals of …, 2016 - annalsofoncology.org
Despite major advances in prevention and treatment, FN remains one of the most frequent
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …
and serious complications of cancer chemotherapy (ChT). It is a major cause of morbidity …
The Multinational Association for Supportive Care in Cancer (MASCC) risk index score: 10 years of use for identifying low-risk febrile neutropenic cancer patients
J Klastersky, M Paesmans - Supportive care in cancer, 2013 - Springer
Abstract The Multinational Association for Supportive Care in Cancer risk index score
developed, through a multinational collaboration, was published in 2000 with the aim to …
developed, through a multinational collaboration, was published in 2000 with the aim to …
[HTML][HTML] Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations
M Aapro, R Boccia, R Leonard, C Camps… - Supportive Care in …, 2017 - Springer
Purpose Chemotherapy-induced febrile neutropenia (FN) causes treatment delays and
interruptions and can have fatal consequences. Current guidelines provide …
interruptions and can have fatal consequences. Current guidelines provide …
[HTML][HTML] A systematic literature review of the efficacy, effectiveness, and safety of filgrastim
DC Dale, J Crawford, Z Klippel, M Reiner… - Supportive Care in …, 2018 - Springer
Abstract Purpose Filgrastim (NEUPOGEN®) is the originator recombinant human
granulocyte colony-stimulating factor widely used for preventing neutropenia-related …
granulocyte colony-stimulating factor widely used for preventing neutropenia-related …
[HTML][HTML] Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in …
K Blackwell, V Semiglazov, D Krasnozhon… - Annals of …, 2015 - Elsevier
Background Biosimilars of filgrastim are in widespread clinical use in Europe. This phase III
study compares biosimilar filgrastim (EP2006), with the US-licensed reference product …
study compares biosimilar filgrastim (EP2006), with the US-licensed reference product …
Human neutrophil kinetics: a call to revisit old evidence
L Koenderman, K Tesselaar, N Vrisekoop - Trends in immunology, 2022 - cell.com
The half-life of human neutrophils is still controversial, with estimates ranging from 7–9 h to
3.75 days. This debate should be settled to understand neutrophil production in the bone …
3.75 days. This debate should be settled to understand neutrophil production in the bone …
[HTML][HTML] Design rationale and development approach for pegfilgrastim as a long-acting granulocyte colony-stimulating factor
T Arvedson, J O'Kelly, BB Yang - BioDrugs, 2015 - Springer
Filgrastim, a recombinant methionyl human granulocyte colony-stimulating factor (G-CSF)(r-
metHuG-CSF), is efficacious in stimulating neutrophil production and maturation to prevent …
metHuG-CSF), is efficacious in stimulating neutrophil production and maturation to prevent …
Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a …
AM Pfeil, K Allcott, R Pettengell, G von Minckwitz… - Supportive care in …, 2015 - Springer
Purpose Pegfilgrastim was introduced over a decade ago. Other long-acting granulocyte
colony-stimulating factors (G-CSFs) have recently been developed. We systematically …
colony-stimulating factors (G-CSFs) have recently been developed. We systematically …